title: Role of splenectomy in chronic lymphocytic leukemia.
abstract: BACKGROUND
  The benefit of splenectomy, performed for complications of chronic lymphocytic leukemia (CLL) including autoimmune hemolytic anemia, thrombocytopenia, hypersplenism, and symptomatic splenomegaly, has not been clearly demonstrated. The objective of this study was to determine if splenectomy achieves a predictable hematologic and survival advantage over conventional chemotherapy in patients with CLL.
  
  
  METHODS
  A retrospective review was performed of 77 consecutive patients with CLL who underwent splenectomy between 1970 and 1994 at the University of Texas M. D. Anderson Cancer Center. Indications for splenectomy, pre- and postoperative hematologic profiles, response to splenectomy, and time to progression and death were recorded. Kaplan-Meier life tables were constructed, and a comparison to an age- and gender-matched cohort of CLL patients treated with fludarabine and no splenectomy was performed using log rank statistical analysis.
  
  
  RESULTS
  Seventy-six percent of the patients studied were Rai stage III/IV. Twenty of 29 patients with hemoglobin counts (Hb) < or = 10 g/dL and 11 of 18 patients with platelet counts (plt) < 50 x 10(9)/L achieved an excellent hematologic response to splenectomy. Splenectomy significantly improved survival in patients with Hb < or = 10 g/dL or plt < or = 50 x 10(9)/L (p = 0.025). Thrombocytopenia did not significantly increase postoperative morbidity, and mortality rate was not significantly different between treatment groups.
  
  
  CONCLUSIONS
  Splenectomy significantly improves survival in selected subgroups of patients with advanced-stage CLL over that achieved with conventional chemotherapy. Based on these results, splenectomy should be performed early in the course of the disease in CLL patients with either an Hb < or = 10 g/dL or plt < or = 50 x 10(9)/L.
authors.affiliation: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Cusack
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: S
authors.initials: S
authors.lastname: Lerner
authors.forename: M J
authors.initials: MJ
authors.lastname: Keating
authors.forename: R E
authors.initials: RE
authors.lastname: Pollock
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000473:pathology / Q000601:surgery*; D015993:Life Tables; D008297:Male; D009367:Neoplasm Staging; D012189:Retrospective Studies; D013156:Splenectomy; D016019:Survival Analysis; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine